Compare IMCR & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMCR | PGY |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | 511 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2016 | N/A |
| Metric | IMCR | PGY |
|---|---|---|
| Price | $34.24 | $17.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $66.33 | $34.50 |
| AVG Volume (30 Days) | 718.5K | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | $14.27 |
| Revenue Next Year | $8.21 | $14.39 |
| P/E Ratio | $136.20 | ★ $13.54 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $10.40 |
| 52 Week High | $40.71 | $44.99 |
| Indicator | IMCR | PGY |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 52.12 |
| Support Level | $30.92 | $16.85 |
| Resistance Level | $34.09 | $19.34 |
| Average True Range (ATR) | 1.62 | 1.19 |
| MACD | 0.19 | -0.16 |
| Stochastic Oscillator | 68.49 | 17.28 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.